Direxion mRNA ETF (MSGR)
NYSEARCA: MSGR · IEX Real-Time Price · USD
19.82 0.06 (0.32%)
Jan 14, 2022 4:00 PM EST - Market closed
| Assets | $3.45M |
| NAV | $19.69 |
| Expense Ratio | 0.65% |
| PE Ratio | n/a |
| Shares Out | 175,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| 1-Year Return | -18.52% |
| Volume | 8,617 |
| Open | 19.71 |
| Previous Close | 19.75 |
| Day's Range | 19.82 - 19.82 |
| 52-Week Low | 19.15 |
| 52-Week High | 19.15 |
| Beta | n/a |
| Holdings | 24 |
| Inception Date | Dec 9, 2021 |
About MSGR
The Direxion mRNA ETF seeks investment results, before fees and expenses, that track the BITA Messenger RNA Technology Index; investing in U.S., Canadian and European companies that are leading the development of messenger RNA technology.
Asset ClassEquity
IssuerDirexion Investments
Stock ExchangeNYSEARCA
Ticker SymbolMSGR
Index TrackedBITA Messenger RNA Technology Index
Top 10 Holdings
66.54% of assets| Name | Symbol | Weight |
|---|---|---|
| Vertex Pharmaceuticals | VRTX | 12.66% |
| Alnylam Pharmaceuticals | ALNY | 7.51% |
| BioNTech SE | BNTX | 7.49% |
| BeiGene | BGNE | 6.52% |
| Ionis Pharmaceuticals | IONS | 6.18% |
| Moderna | MRNA | 5.86% |
| Arrowhead Pharmaceuticals | ARWR | 5.79% |
| ProQR Therapeutics | PRQR | 5.17% |
| Arcturus Therapeutics Holdings | ARCT | 4.72% |
| Sarepta Therapeutics | SRPT | 4.64% |
News
Direxion Launches mRNA Technology-Focused ETF
Direxion has announced today in a press release the launch of their newest ETF that focuses on the applications and developments of messenger RNA technology, the Direxion mRNA ETF (MSGR). The fund looks...
1 month ago - ETF Trends
Direxion Launches mRNA ETF (MSGR)
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies believed to be at the forefront of the development and app...
1 month ago - PRNewsWire